Growing Prevalence Of Alzheimer And Multi-Infarct Dementia Boosting The Global Multi-Infarct Dementia Market

According to a recently published report, the global Multi-Infarct Dementia Market has been expected to grow $13400milliontill 2022with the CAGR of 12.7% during 2016-2022. The segmentation of global multi-infarct dementia market is based on causes of dementia, pharmacological treatment and regional outlook. The report on global multi-infarct dementia market forecast 2016-2022 (causes of dementia, pharmacological treatment andregional outlook) provides detailed overview and predictive analysis of the market.

Full report is available onglobal multi-infarct dementia market forecast 2016-2022 (causes of dementia, pharmacological treatment and regional outlook) report at http://www.briskinsights.com/report/multi-infarct-dementia-market

The multi infarct dementia is a series of minor brain strokes which acts as a disruption in the flow of blood in the brain. According to National Institute of Aging,multi-infarct dementia and alzheimer disease is the common form of dementia. This type of diseases are mainly found in elders, 1 out of 3 senior citizens dies with alzheimer diseases or another dementia. There are various symptoms of multi-infarct dementia like repetitive movement, agitation, insomnia, memory loss, depression, loss of reasoning abilities and so on. Either mental functioning orwhole memory loss may occur in the final or advance stages of the disease or it may even cause the death of a person.Large number of deaths are caused by this severe diseases as compared to the lives taken bybreast and prostate cancer. The global multi-infarct dementia market has been growing with the rapid rise in the prevalence ofmulti-infarct dementia diseases. Majorly the multi-infarct dementia is found in the peoples with age 60 plus. Brain power is reduced and the patientsare unable to react normally. The increasing occurrence rate and growing prevalence of alzheimer diseases is lifting the multi-infarct dementia market upward.

Scope of the report

1. GLOBAL MULTI-INFARCT DEMENTIA MARKET BY CAUSES OF DEMENTIA 2012 - 2022 ($ million)
1.1. Anemia
1.2. Brain Tumor
1.3. Chronic Infection
1.4. Depression
1.5. Thyroid Disease
1.6. Vitamin Deficiency
1.7. Drug Intoxication

2. GLOBAL MULTI-INFARCT DEMENTIA MARKET BY PHARMACOLOGICAL TREATMENT 2012 - 2022 ($ million)
2.1. Cholinesterase Inhibitors (Cheis)
2.1.1. Donepezil
2.1.2. Galantamine
2.1.3. Rivastigmine
2.2. Memantine
2.3. Nimodipine
2.4. Hydergine
2.5. Cytidine 5′-Diphosphocholine (CDP-Choline)

3. GLOBAL MULTI-INFARCT DEMENTIA MARKET REGIONAL OUTLOOK 2012-2022($ million)
3.1. North America
3.2. Europe
3.3. Asia Pacific
3.4. Rest of the world

4. Company Profiles
4.1. Accelerys Inc.
4.2. Affymetrix
4.3. Agilent technologies
4.4. Celera Corporation
4.5. DNAnexus
4.6. Forest Laboratories, Inc.
4.7. Geneva Bioinformatics
4.8. GVK Biosciences
4.9. IBM Life sciences
4.10. Illumina Inc.
4.11. Janssen Pharmaceuticals, Inc.
4.12. Life Technologies Corporation
4.13. Novartis Pharmaceutical Corporation
4.14. Pfizer, Inc.
4.15. Siegen Inc.